Future oncology (London, England), Volume 16, Issue 12, 31 March 2020, Pages 749-762 Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer. Ponce Aix S, Talbot D, Govindan R, Dols MC, Postmus PE, Lewanski C, Bennouna J, Fischer JR, Juan-Vidal O, Stewart DJ, Ardizzoni A, Bhore R, Wolfsteiner M, Reck M, Ong TJ, Morgensztern D

Aim

Evaluate quality of life (QoL) in patients with advanced non-small cell lung cancer treated with second or third line nab-paclitaxel ± durvalumab. Patients & methods

Longitudinal QoL was assessed using Lung Cancer Symptom Scale, EuroQoL Five-Dimensions Five-Levels and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core. Results

QoL was generally stable through eight treatment cycles (both arms). Clinically meaningful improvement from baseline was noted in Lung Cancer Symptom Scale (overall constitutional score and three-item index [nab-paclitaxel + durvalumab]) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core (global health status/QoL and emotional functioning [both arms] and pain [nab-paclitaxel + durvalumab]) analyses. EuroQoL Five-Dimensions Five-Levels domains were stable/improved or completely resolved at least once in 19-56% and 9-51% of patients, respectively. Conclusion

While QoL trends were promising, additional data are required to support these regimens in this setting.

Keywords: Non-small cell lung cancer, Quality of life, Nab-paclitaxel, Lung Cancer Symptom Scale, Eortc Qlq-c30, Eq-5d-5l, Durvalumab

Future Oncol. 2020 Mar;16(12):749-762